Topics

Companies Related to "CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study" [Most Relevant Company Matches] RSS

05:49 EST 24th January 2020 | BioPortfolio

Here are the most relevant search results for "CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study" found in our extensive corporate database of over 50,000 company records.

Showing "Oral Therapy Addition Standard Antidepressant Drug Major Depressive" Companies 1–25 of 8,000+

Relevant

Greenbrook TMS Inc.

Operating through 47 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (TMS), an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with...


Lipocine, Inc.

Lipocine Inc. is a specialty pharmaceutical company developing innovative products for use in men’s and women’s health using its proprietary drug delivery technologies. Lipocine’s lead product candidate, LPCN 1021, is Phase III ready and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Th...

CiTrials

At Clinical Innovations, our mission is to conduct Phase I-IV clinical trials in order to further the development of medications benefiting patients, communities, and physicians around the globe. Located in Southern California, CiTrials has the experience and expertise in performing Psychiatric and Internal medicine trials. From pediatric, first in human, single and multiple ascending dose, and...


Sierra Neuropharmaceuticals, Inc.

Sierra Neuropharmaceuticals is a biopharmaceutical company focused on the development and commercialization of centrally-administered, small molecule therapeutics for the treatment of severe CNS diseases refractory to oral medications. These include epilepsy, schizophrenia, bipolar disorder, anxiety disorders and major depression. The company uses a proprietary drug development process to refo...

Targacept, Inc.

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Tar...

TMS Center of Colorado

TMS Center of Colorado is a group of compassionate, caring physicians and technicians committed to your health. Our center’s focus is state-of-the-art outpatient treatment of major depressive disorders through the use of repetitive transcranial magnetic stimulation (deep TMS, rTMS or TMS).TMS is the only non-systemic and non-invasive treatment for suc...

IntraBiotics Pharmaceuticals Incorporated

The mission of IntraBiotics is to develop and commercialize novel antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases. IntraBiotics has developed two new antibiotics, Ramoplanin Oral and Protegrin IB-367 Rinse, to the third stage of clinical trials. Ramoplanin Oral and Protegrin IB-367 Rinse are both new types of antibiotics that may address major medi...

Rebiotix Inc.

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for th...

Erimos Technologies, LLC

Erimos has exclusive license for nordihydroguaiaretic acid (NDGA) derivatives from The Johns Hopkins University. We have developed a novel process to extract NDGA from the resin of the leaves of Larrea tridentata, a desert plant indigenous to the southwestern US and Mexico. EM-1421, our lead candidate, is a semi-synthetic derivative of NDGA. It is designed to target specific differences between no...

The Standard

The Standard Charitable Foundation is the independent charitable and philanthropic arm of The Standard. Founded in 2006, the Foundation’s mission is to make a positive difference in communities by supporting community development, education, disability and health organizations. While the Foundation has a broad goal of making a positive difference in c...

Targacept Inc.

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Tar...

Pear Therapeutics

Pear Therapeutics is the leader in prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. ...

RenalGuard Solutions, Inc.

RenalGuard measures a patient's urine output and automatically infuses hydration fluid based on that urine output. The system is designed to induce high urine rates, which have been shown to protect the kidney from a range of insults. A number of studies have demonstrated RenalGuard's ability to protect patients from AKI following catheterization procedure...

NeuroRx, Inc.

NeuroRx, Inc. is a privately funded, clinical-stage pharmaceutical company, developing NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Ideation and Behavior (ASIB) in bipolar depression. NeuroRx draws upon 30 years of basic science and clinical expertise in the role of the N-methyl-D-aspartate (NMDA), a receptor that regulates human...

Naurex, Inc.

Naurex, Inc. is a private company developing novel therapies for depression and other CNS disorders based on the work of founder Dr. Joseph R. Moskal and colleagues who discovered a new mechanism of action for modulating the NMDA receptor. Naurex has used these discoveries to generate novel chemical drug classes known as glycine site functional partial agonists (GFPAs). Naurex's first GFPA NMDA ...

Newron Pharmaceuticals S.p.A.

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patie...

ApniCure, Inc.

ApniCure is a private Redwood City, Calif.-based medical device company focused on developing and commercializing novel home-use devices incorporating a proprietary platform technology called Oral Pressure Therapy (OPT) for the treatment of obstructive sleep apnea (OSA) and other sleep related disorders. The U.S. Food and Drug Administration (FDA) granted ...

Synovics Pharmaceuticals

Synovics is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of oral controlled-release generic drugs and improved formulations of previously approved drugs. The Company has licensed exclusive and worldwide rights to employ certain proprietary oral controlled-release drug formulation technologies. Synovics is undertaking the initiation of US develo...

Adaptive Phage Therapeutics, Inc. (APT)

Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. APT’s core asset is a large and continually expanding phage library (PhageBankTM) deployed with a companion diagnostic to achieve rapid response and cost-effective therapy for otherwise recalcitrant bact...

Mycovia Pharmaceuticals, Inc.

Mycovia Pharmaceuticals has a passion for developing breakthrough therapies in areas of unmet medical need, with an initial focus in women’s health. Our lead product candidate, VT-1161, is a novel, oral therapy for RVVC that is designed to have greater selectivity, fewer side effects and improved efficacy than current treatment options. VT-1161 received FDA Qualified Infectious Disease Produ...

PhotoCure

PhotoCure is engaged in the research and development of novel therapeutics and diagnostics and related medical devices based on its proprietary photodynamic therapy (PDT) technologies. PDT is a two step process involving the application of a drug known as a photosensitiser followed by controlled exposure to a selective light source that activates the drug. In addition, PhotoCure is employing photo...

Agennix

Agennix is a privately held biotechnology company whose lead molecule, Talactoferrin Alfa (talactoferrin; TLF), is an immunomodulatory protein. Agennix is currently preparing to initiate Phase III development of oral talactoferrin for cancer, and topical talactoferrin gel for wound healing.Liquid talactoferrin is an oral anti-cancer drug that has shown activity both as monotherapy and in combinati...

Urovant Sciences Ltd.

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant’s lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinar...

Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant’s lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinar...

Gold Standard/Elsevier

Based in Tampa, FL, Gold Standard/ELSEVIER uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Gold Standard/ELSEVIER solutions empower healthcare organizations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes. To...


More From BioPortfolio on "CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study"

Quick Search

Corporate Database Quicklinks